$5.08-1.9%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 5, 2026
Just reported
From Entrada Therapeutics, Inc.'s results release of November 5, 2026; its quarterly report has since been filed.
Actual
$905K
-44% y/y
+0.8% q/q
Guided
—
No guide given
Actual
-$0.94
Guided
—
No guide given
Actual
-$41.7M
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $905K | $1.6M | -43.93% |
| Profit | -$39.7M | -$44.1M | +9.95% |
| Profit per share | -$0.94 | -$1.06 | +11.32% |
| Free Cash Flow | -$30.1M | -$28.1M | -7.05% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Entrada Therapeutics, Inc. reported on November 5, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“The October Cohort 1 data from ELEVATE-45-201 marked our third consecutive readout demonstrating encouraging safety and tolerability across our clinical programs,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of genetic medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary, versatile and modular approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company’s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Entrada Therapeutics, Inc.’s Item 2.02 8-K filed November 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.